Wire · operational-macro
FDA Grants Accelerated Approval to Jemperli
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 October 2026 · Fusion42 review
The FDA granted accelerated approval to GSK's immunotherapy Jemperli for MSI-H/dMMR locally advanced rectal cancer based on Phase II trial results with a 68% 12-month response rate. This approval marks Jemperli as the first and only immunotherapy for this specific cancer type, pending confirmatory trials for continued approval.
This Wire brief sits within Fusion42's coverage of Biotech, and 15 sources have reported it between 19 Oct 2026 and 25 Oct 2026.
◆ ◆ The Wire takeaway
You face a new entry point in immunotherapy with Jemperli's FDA accelerated approval for rectal cancer setting biomarker testing as critical. This opens immediate opportunities to engage oncology treatment providers focused on MSI-H/dMMR cancers.
◆ Coverage
15 sources · first reported 19 Oct 2026 · latest 25 Oct 2026
◆ Related on Wire
◆ Topics